BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

465 related articles for article (PubMed ID: 19205737)

  • 1. Current treatment options in dermatofibrosarcoma protuberans.
    Lemm D; Mügge LO; Mentzel T; Höffken K
    J Cancer Res Clin Oncol; 2009 May; 135(5):653-65. PubMed ID: 19205737
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dermatofibrosarcoma protuberans: recent clinical progress.
    McArthur G
    Ann Surg Oncol; 2007 Oct; 14(10):2876-86. PubMed ID: 17647063
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Remission with Imatinib mesylate treatment in a patient with initially unresectable dermatofibrosarcoma protuberans--a case report.
    Lemm D; Muegge LO; Hoeffken K; Aklan T; Mentzel T; Thorwarth M; Schultze-Mosgau S
    Oral Maxillofac Surg; 2008 Dec; 12(4):209-13. PubMed ID: 18751744
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecularly targeted treatment for dermatofibrosarcoma protuberans.
    McArthur G
    Semin Oncol; 2004 Apr; 31(2 Suppl 6):30-6. PubMed ID: 15176002
    [TBL] [Abstract][Full Text] [Related]  

  • 5. From Morphea to Dermatofibrosarcoma Protuberans.
    Crnarić I; Šitum M; Delaš Aždajić M; Vučić M; Buljan M
    Acta Dermatovenerol Croat; 2022 Sep; 30(2):113-115. PubMed ID: 36254545
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Target therapy of unresectable or metastatic dermatofibrosarcoma protuberans with imatinib mesylate: an analysis on 22 Chinese patients.
    Wang C; Luo Z; Chen J; Zheng B; Zhang R; Chen Y; Shi Y
    Medicine (Baltimore); 2015 May; 94(17):e773. PubMed ID: 25929918
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular targeting of dermatofibrosarcoma protuberans: a new approach to a surgical disease.
    McArthur GA
    J Natl Compr Canc Netw; 2007 May; 5(5):557-62. PubMed ID: 17509258
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Dermatofibrosarcoma protuberans].
    Sanmartín O; Llombart B; López-Guerrero JA; Serra C; Requena C; Guillén C
    Actas Dermosifiliogr; 2007 Mar; 98(2):77-87. PubMed ID: 17397592
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Using imatinib as neoadjuvant therapy in dermatofibrosarcoma protuberans: potential pluses and minuses.
    Johnson-Jahangir H; Sherman W; Ratner D
    J Natl Compr Canc Netw; 2010 Aug; 8(8):881-5. PubMed ID: 20870634
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Long-term experience with multidisciplinary therapy of twenty-six patients with dermatofibrosarcoma protuberans].
    Mátrai Z; Liszkay G; Plotár V; Orosz Z; Székely J; Hitre E; Bartal A; Langmár Z; Bocs K; Rényi Vámos F; Sávolt A; Tóth L
    Orv Hetil; 2009 Oct; 150(41):1894-902. PubMed ID: 19801356
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential sensitivity to imatinib of 2 patients with metastatic sarcoma arising from dermatofibrosarcoma protuberans.
    Maki RG; Awan RA; Dixon RH; Jhanwar S; Antonescu CR
    Int J Cancer; 2002 Aug; 100(6):623-6. PubMed ID: 12209598
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dermatofibrosarcoma protuberans: is mohs surgery truly superior? And the success of tyrosine kinase inhibitors.
    Kallini JR; Khachemoune A
    J Drugs Dermatol; 2014 Dec; 13(12):1474-7. PubMed ID: 25607791
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Complete resection of recurrent and initially unresectable dermatofibrosarcoma protuberans downsized by Imatinib.
    Wicherts DA; van Coevorden F; Klomp HM; van Huizum MA; Kerst JM; Haas RL; van Boven HH; van der Hage JA
    World J Surg Oncol; 2013 Mar; 11():59. PubMed ID: 23496933
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dermatofibrosarcoma protuberans: a comprehensive review and update on diagnosis and management.
    Llombart B; Serra-Guillén C; Monteagudo C; López Guerrero JA; Sanmartín O
    Semin Diagn Pathol; 2013 Feb; 30(1):13-28. PubMed ID: 23327727
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [New molecular approaches in dermatofibrosarcoma protuberans].
    Kaya G
    Rev Med Suisse; 2009 Jul; 5(211):1519-24. PubMed ID: 19694363
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neoadjuvant imatinib therapy for dermatofibrosarcoma protuberans.
    Han A; Chen EH; Niedt G; Sherman W; Ratner D
    Arch Dermatol; 2009 Jul; 145(7):792-6. PubMed ID: 19620561
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Response of malignant scalp dermatofibrosarcoma to presurgical targeted growth factor inhibition.
    Mattox AK; Mehta AI; Grossi PM; Cummings TJ; Adamson DC
    J Neurosurg; 2010 May; 112(5):965-77. PubMed ID: 19681684
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dermatofibrosarcoma Protuberans.
    Allen A; Ahn C; Sangüeza OP
    Dermatol Clin; 2019 Oct; 37(4):483-488. PubMed ID: 31466588
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current treatment options for dermatofibrosarcoma protuberans.
    Rutkowski P; Debiec-Rychter M
    Expert Rev Anticancer Ther; 2015; 15(8):901-9. PubMed ID: 26027711
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mohs micrographic surgery for the treatment of dermatofibrosarcoma protuberans. Results of a multiinstitutional series with an analysis of the extent of microscopic spread.
    Ratner D; Thomas CO; Johnson TM; Sondak VK; Hamilton TA; Nelson BR; Swanson NA; Garcia C; Clark RE; Grande DJ
    J Am Acad Dermatol; 1997 Oct; 37(4):600-13. PubMed ID: 9344201
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.